

Resource Summary Report

Generated by ASWG on Aug 10, 2026

CD34 APC

RRID:AB_2686894

Type: Antibody

Proper Citation

BD Biosciences Cat# 345804, RRID:AB_2686894

Antibody Information

URL: http://antibodyregistry.org/AB_2686894

Proper Citation: BD Biosciences Cat# 345804, RRID:AB_2686894

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Antibody Name: CD34 APC

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: 8G12

Antibody ID: AB_2686894

Vendor: BD Biosciences

Catalog Number: 345804

Record Creation Time: 20250819T211229+0000

Record Last Update: 20250819T221212+0000

Ratings and Alerts

No rating or validation information has been found for CD34 APC.

No alerts have been found for CD34 APC.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Haladik B, et al. (2025) Image-based drug screening combined with molecular profiling identifies signatures and drivers of therapy resistance in pediatric AML. *Cell reports. Medicine*, 6(9), 102304.

Kaiser FMP, et al. (2023) IL-7 receptor signaling drives human B-cell progenitor differentiation and expansion. *Blood*, 142(13), 1113.

Brabson JP, et al. (2023) Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia. *Cell reports*, 42(1), 112027.

Cieřla M, et al. (2023) m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. *Molecular cell*, 83(7), 1165.

Zhu H, et al. (2020) Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. *Cell stem cell*, 27(2), 224.

Li Y, et al. (2018) Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. *Cell stem cell*, 23(2), 181.